BIC Announces No Trading in Own Shares for July 2025
PorAinvest
viernes, 1 de agosto de 2025, 11:46 am ET1 min de lectura
UTHR--
The repurchase program reflects the company's confidence in its stock's intrinsic value and its ability to generate sustained revenue and cash flow growth. Final settlement for the uncollared ASR is expected in the fourth quarter of 2025, while the collared ASR should settle in the first quarter of 2026. The final number of shares repurchased will be based on the average daily volume-weighted average price during the term of the agreements. United Therapeutics had approximately 45.2 million shares outstanding as of July 30, 2025 [1].
Meanwhile, the broader market has remained relatively flat over the past week, with no significant sector-specific movements. However, over the past year, the market has experienced a 4.8% growth, and earnings are expected to grow by 7.7% per annum over the next few years [2].
In related news, BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products [3].
References:
[1] https://www.investing.com/news/stock-market-news/united-therapeutics-stock-jumps-on-1-billion-share-repurchase-plan-93CH-4165687
[2] https://simplywall.st/stock/tse/3048
[3] https://www.globenewswire.com/news-release/2025/07/30/3124284/0/en/BIC-First-Half-2025-Results.html
BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products.
United Therapeutics Corporation (NASDAQ: UTHR) stock experienced a 4% increase on Friday morning following the announcement of a $1 billion accelerated share repurchase (ASR) program. The company entered into two ASR agreements with Citibank, N.A., totaling $1 billion, with an initial upfront payment of $1 billion on August 4, 2025. The agreements include a $500 million collared and a $500 million uncollared agreement. United Therapeutics will receive approximately 75% of shares under the uncollared agreement and about 50% under the collared agreement [1].The repurchase program reflects the company's confidence in its stock's intrinsic value and its ability to generate sustained revenue and cash flow growth. Final settlement for the uncollared ASR is expected in the fourth quarter of 2025, while the collared ASR should settle in the first quarter of 2026. The final number of shares repurchased will be based on the average daily volume-weighted average price during the term of the agreements. United Therapeutics had approximately 45.2 million shares outstanding as of July 30, 2025 [1].
Meanwhile, the broader market has remained relatively flat over the past week, with no significant sector-specific movements. However, over the past year, the market has experienced a 4.8% growth, and earnings are expected to grow by 7.7% per annum over the next few years [2].
In related news, BIC, a global stationery and lighters company, disclosed no transactions in its own shares for July 2025. The company's next financial updates include Q3 2025 net sales on October 28, 2025, and full-year 2025 results on February 24, 2026. BIC has a presence in over 160 countries and a portfolio of iconic brands and products [3].
References:
[1] https://www.investing.com/news/stock-market-news/united-therapeutics-stock-jumps-on-1-billion-share-repurchase-plan-93CH-4165687
[2] https://simplywall.st/stock/tse/3048
[3] https://www.globenewswire.com/news-release/2025/07/30/3124284/0/en/BIC-First-Half-2025-Results.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios